Log In
BCIQ
Print this Print this
 

etelcalcetide (AMG 416, ONO-5163) (formerly KAI-4169)

Also known as: formerly Velcalcetide

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionPeptide calcimimetic that acts on the parathyroid gland to reduce production of parathyroid hormone (PTH)
Molecular Target Calcium sensing receptor (CaSR)
Mechanism of ActionCalcium-sensing receptor (CaSR) agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentRegistration
Standard IndicationThyroid disease
Indication DetailsTreat secondary hyperparathyroidism (SHPT); Treat secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiving hemodialysis
Regulatory Designation
PartnerAllergan plc;
Ono Pharmaceutical Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$315.0M

$328.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/16/2012

$315.0M

$315.0M

0

09/19/2011

Undisclosed

$13.0M

Undisclosed

Get a free BioCentury trial today